{'fraction_non_alphanumeric': 0.014598540145985401, 'fraction_numerical': 0.0036496350364963502, 'mean_word_length': 5.168539325842697, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
THE AUSTRALIAN RIFAMPICIN TRIAL

Rifampicin is a new broad‐spectrum antibiotic, active against Mycobacterium tuberculosis and some atypical mycobacteria. It is highly bactericidal at clinically attainable serum levels; at lower levels it is bacteriostatic. Data on serum and urine rifampicin levels have been gathered on a majority of 54 patients in the Australian Trial. An evaluation of side effects and toxicity is presented, and a detailed evaluation of the effect of rifampicin on liver function is the subject of the second part of the paper.